

TITAN PHARMACEUTICALS INC

Form 8-K

September 28, 2015

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): September 28, 2015

Titan Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware                                      0-27436                                      94-3171940  
(State or Other Jurisdiction of      (Commission File Number) (IRS Employer Identification No.)  
Incorporation)

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080  
(Address of Principal Executive Offices)                                      (Zip Code)

Registrant's telephone number, including area code: 650-244-4990

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On September 28, 2015, Titan Pharmaceuticals, Inc. (the “Company”) announced that the FDA has accepted for review the New Drug Application (“NDA”) for Probuphine® and has set February 27, 2016 as the target date for action on the NDA.

A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference,

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

**Exhibit No. Description**

99.1 Press Release, dated September 28, 2015.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 28, 2015  
TITAN  
PHARMACEUTICALS,  
INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: President

**Exhibit Index**

**Exhibit No. Description**

99.1 Press Release, dated September 28, 2015.